We successful signed a strategic equity investment agreement with ShangHai Celgen Bio-pharmacevtical.CO.,LTD in Mar 2008, and invested them RMB 20 million. This company was created by Shanghai Pharmacy company group and American Handa Biotech Holdings .CO.,LTD with registered capital of 140 million, which focuses on the cell engineering. The company has the world leading technology platform of recombinant protein expression, whose biological drugs for treatment of ankylosing spondylitis have broadly market prospects and highly commercial value. |